- Home
- HURA vs CRBP Comparison
HURA vs CRBP Comparison
Compare HURA & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | CRBP |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | United States | United States |
| Employees | 22 | 36 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 168.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | HURA | CRBP |
|---|---|---|
| Price | $2.07 | $8.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $9.50 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 327.9K | 305.2K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $0.41 | $7.12 |
| 52 Week High | $3.90 | $20.56 |
Technical Indicators
Market Signals| Indicator | HURA | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 50.44 |
| Support Level | $1.82 | $7.86 |
| Resistance Level | $2.20 | $9.73 |
| Average True Range (ATR) | 0.14 | 0.46 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 1.32 | 42.28 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.